Bruker (NASDAQ:BRKR) Shares Break Below 50 Day Moving Average – Time to Sell?

Bruker Corporation (NASDAQ:BRKR – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $59.99 and traded as low as $56.13. Bruker shares last traded at $56.46, with a volume of 2,250,882 shares.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. downgraded shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 target price for the company. in a research report on Wednesday, October 14th. Leerink Partners boosted their price target on shares of Bruker from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. Zacks Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Citigroup boosted their price objective on Bruker from $53.00 to $64.00 and gave the stock a “hold” rating in a research note on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $61.00.

Get Our Latest Analysis on Bruker

Bruker Stock Down 9.1%

The company has a debt-to-equity ratio of 0.74, a current ratio of 1.84 and a quick ratio of 0.90. The company has a market capitalization of $8.62 billion, a price-to-earnings ratio of -51.33, a PEG ratio of 1.76 and a beta of 1.26. The business has a 50 day simple moving average of $59.99 and a 200 day simple moving average of $51.31.

Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.14. Bruker had a negative net margin of 3.82% and a positive return on equity of 13.76%. The business had revenue of $874.00 million for the quarter, compared to analysts’ expectations of $865.16 million. During the same quarter in the prior year, the company earned $0.45 earnings per share. The business’s quarterly revenue was up 1.6% on a year-over-year basis. As a group, equities analysts predict that Bruker Corporation will post 2.13 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 7th. Stockholders of record on Monday, December 21st will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s payout ratio is currently -18.18%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president directly owned 134,806 shares in the company, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

Institutional investors have recently modified their holdings of the stock. American Century Companies Inc. grew its holdings in shares of Bruker by 64.1% during the third quarter. American Century Companies Inc. now owns 45,966 shares of the medical research company’s stock worth $2,976,000 after purchasing an additional 17,957 shares during the last quarter. Kestra Advisory Services LLC raised its position in Bruker by 6.0% during the 3rd quarter. Kestra Advisory Services LLC now owns 4,947 shares of the medical research company’s stock worth $320,000 after buying an additional 282 shares during the last quarter. Coastal Bridge Advisors LLC acquired a new stake in Bruker in the third quarter valued at about $254,000. Integrated Wealth Concepts LLC boosted its position in shares of Bruker by 14.9% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 8,491 shares of the medical research company’s stock worth $550,000 after purchasing an additional 1,101 shares in the last quarter. Finally, Allworth Financial LP grew its position in Bruker by 40.3% during the third quarter. Allworth Financial LP now owns 5,434 shares of the medical research company’s stock worth $352,000 after buying an additional 1,561 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

(Get Free Report)

Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company’s offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.

Recommended Stories

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.